As much as TAVR's popularity has grown in recent years, there are still many instances when a heart team may find that surgery offers the best path forward. 

SCAI and the Association of Black Cardiologists have joined forces to share a simple message: PAD patients would be negatively impacted by new CMS proposals. 

Using the World Health Organization’s model for analyzing gender-related healthcare needs, the authors of a new analysis aimed to explore disparities in PAD outcomes.

Atul Verma, MD, director of cardiology at McGill University Health Centre in Montreal, explained why the late-breaking PULSED-AF trial data on Medtronic’s pulsed-field ablation technology is so important for cardiologists. 

The study, to be presented March 5 at ACC.23/WCC in New Orleans, examined outcomes data from 1999 to 2020. 

Sahil Parikh, MD, director of endovascular services at Columbia University Irving Medical Center, said treating these patients can be quite challenging. 

The annual list, now in its 17th year, was designed to celebrate companies that make ethical business practices a high priority. 

SGLT2 inhibitors such as dapagliflozin and empagliflozin are associated with improved outcomes among many heart failure patients. The medications are not cost-effective, however, limiting their overall value. Read the full economic analysis to learn more.